NASDAQ · Key Statistics

Halozyme Therapeutics, Inc. (HALO) Key Statistics

$125.63 NASDAQ: HALO Market Cap $14.26B

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Halozyme Therapeutics, Inc. (HALO), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

Metric	Value
P/E ratioShare price divided by earnings per share.	30.77
P/B ratioShare price divided by book value per share.	88.49
P/S ratioMarket value divided by annual revenue.	7.72
PEG ratioP/E divided by the earnings growth rate.	-1.44
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.	20.77
EV / RevenueEnterprise value against annual revenue.	8.91
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.	3.19%
Free cash flow yieldFree cash flow as a percentage of market value.	6.28%
Price / free cash flowMarket value divided by free cash flow.	20.06

Profitability

Metric	Value
Gross marginRevenue left after the direct cost of goods sold.	78.18%
Operating marginRevenue left after operating costs.	56.77%
Net marginRevenue left after every cost, including tax and interest.	24.86%
Return on equityProfit as a percentage of shareholders’ equity.	180.63%
Return on assetsProfit as a percentage of total assets.	16.05%
Return on capital employedOperating profit against the capital the business uses.	42.30%

Financial health

Metric	Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.	2.71
Quick ratioThe same, excluding inventory.	2.31
Cash ratioCash alone against current liabilities.	0.76
Debt to equityTotal borrowings against shareholders’ equity.	14.95
Debt to assetsTotal borrowings against total assets.	0.85
Interest coverageHow many times operating profit covers the interest bill.	46.52

Per share and size

Metric	Value
Earnings per shareProfit attributable to each share.	$2.56
Shares outstandingShares currently issued.	0
Market capitalisationShare price times shares outstanding.	$14.26B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.	$16.15B
EmployeesReported headcount.	423

Dividend

Metric	Value
Dividend yieldAnnual dividend as a percentage of the share price.	0.00%

Halozyme Therapeutics, Inc. (HALO) statistics — frequently asked questions

What is Halozyme Therapeutics, Inc.'s P/E ratio?

Halozyme Therapeutics, Inc. (HALO) trades on a price-to-earnings ratio of 30.77.

What is Halozyme Therapeutics, Inc.'s return on equity?

Halozyme Therapeutics, Inc. (HALO) reports a return on equity of 180.63%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Halozyme Therapeutics, Inc. carry?

Halozyme Therapeutics, Inc. (HALO) has a debt-to-equity ratio of 14.95, which compares total borrowings with shareholders' equity.

What is Halozyme Therapeutics, Inc.'s profit margin?

Halozyme Therapeutics, Inc. (HALO) keeps 24.86% of revenue as net profit after every cost, including tax and interest.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.